Metameconine

Metameconine

SCHEMBL800990

COc1cc2c(cc1OC)C(=O)OC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 1.00
MAPT P10636 6/20 0.60
HTT P42858 5/20 0.60
LMNA P02545 4/20 0.58
HPGD P15428 1/20 0.58
MAPK1 P28482 2/20 0.56
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.47
ACHE P22303 1/20 0.47
CYP19A1 P11511 1/20 0.46
GAA P10253 1/20 0.46
PRF1 P14222 1/20 0.46
IMPDH2 P12268 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PDE5A O76074 1/20 0.44
PDE4A P27815 1/20 0.44
PDE1A P54750 1/20 0.44
PDE1B Q01064 1/20 0.44
PDE4B Q07343 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Metameconine SCHEMBL30088952 1.00 CYP3A4 (1.00) CYP3A4MAPTHTTLMNAHPGD
SCHEMBL32666934 0.87 CYP3A4 (0.77) CYP3A4MAPTHTTLMNAHPGD
SCHEMBL28621689 0.87 CYP3A4 (0.77) CYP3A4MAPTHTTLMNAHPGD
SCHEMBL31083089 0.87 CYP3A4 (0.77) CYP3A4MAPTHTTLMNAHPGD
SCHEMBL30018390 0.87 CYP3A4 (0.77) CYP3A4MAPTHTTLMNAHPGD
SCHEMBL27094963 0.87 CYP3A4 (0.77) CYP3A4MAPTHTTLMNAHPGD
Hydrochloric Acid SCHEMBL31216865 0.86 CYP3A4 (0.75) CYP3A4MAPTHTTLMNAHPGD
SCHEMBL7000739 0.86 CYP3A4 (0.75) CYP3A4MAPTHTTLMNAHPGD
SCHEMBL6202478 0.80 CYP3A4 (0.67) CYP3A4MAPTHTTLMNAHPGD
SCHEMBL15094387 0.80 CYP3A4 (0.63) CYP3A4MAPTHTTLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0013617-B1 PENICILLIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING CERTAIN OF THESE COMPOUNDS BEECHAM GROUP PLC (GB) 1984-07-04 EP claimed
CN-118355016-A SOS1 inhibitors 北京望实智慧科技有限公司 2024-07-16 CN disclosed
CN-115260136-B Phthalide compound and preparation method thereof 嘉兴学院 2023-08-15 CN disclosed
WO-2023116902-A1 SOS1 INHIBITOR 北京望实智慧科技有限公司 2023-06-29 WO disclosed
US-20230159469-A1 NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2023-05-25 US disclosed
US-20230159469-A1 NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2023-05-25 US disclosed
EP-4148046-A1 NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE INHIBITORY ACTIVITY, AND USE THEREOF Txinno Bioscience Inc. (KR) 2023-03-15 EP disclosed
WO-2023287730-A1 TRICYCLIC COMPOUNDS RECURIUM IP HOLDINGS, LLC (US) 2023-01-19 WO disclosed
US-11008282-B2 Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease KOESTER HUBERT (CH) 2021-05-18 US disclosed
CN-107163012-B 3-alkyl-5, 6-dioxygen substituted phthalide compounds and preparation method and application thereof 四川大学 2020-08-04 CN disclosed
EP-1245565-A1 Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2002-10-02 EP disclosed
EP-1241169-A1 Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2002-09-18 EP disclosed
US-20020058662-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors ZAMBON GROUP S.P.A. (IT) 2002-05-16 US disclosed
US-6340684-B1 TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, ALLERGIC RHINITIS ZAMBON GROUP S.P.A. (IT) 2002-01-22 US disclosed
EP-1124829-A1 TRICYCLIC PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2001-08-22 EP disclosed
EP-1098886-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2001-05-16 EP disclosed
EP-1042300-A1 PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2000-10-11 EP disclosed
WO-2000026218-A1 TRICYCLIC PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 2000-05-11 WO disclosed
WO-2000005219-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 2000-02-03 WO disclosed
WO-1999032456-A1 PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058662-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 CYP3A4 186/4885MAPT 2777/4885HTT 3878/4885
US-20230159469-A1 NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF ENPP1, ENPP3, PPA1 CYP3A4 4632/4885MAPT 2828/4885HTT 1802/4885
US-11008282-B2 Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease COMT, PNMT, DBH CYP3A4 133/4885MAPT 1468/4885HTT 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.